Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to ...

This signature reveals a fundamental, disease-independent vulnerability linked to APOE ε4, reframing our understanding of genetic risk in conditions like Alzheimer's, Parkinson’s, ALS, and FTD.

Scientists discover the receptor that helps your brain clean itself—and fight Alzheimer’s Date: July 27, 2025 Source: University of California - San Francisco Summary: Scientists at UCSF have ...

BACKGROUND: Abdominal aortic aneurysm (AAA) is a life-threatening vascular disease with no effective pharmacological treatments. The causal role of triglycerides (TGs) in AAA development remains ...

Voyager Therapeutics announces a new program targeting APOE4 in Alzheimer's patients, combining gene therapy and novel delivery methods.

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks ...

Walking and other lifestyle habits may slow cognitive decline in APOE ε4 carriers — possibly offering greater benefits than in noncarriers, new research suggests.

APOE ε4 has been linked to a lower age of onset and a higher risk of Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD).

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with ...